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Abstract
Background: Approximately 826,000 children, mostly young infants, die annually from invasive pneumococcal disease. A 6-
10-14-week schedule of pneumococcal conjugate vaccine (PCV) is efficacious but neonatal PCV may provide earlier
protection and better coverage. We conducted an open randomized controlled trial in Papua New Guinea to compare
safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in a 0-1-2-month (neonatal) schedule with
that of the routine 1-2-3-month (infant) schedule.
Methods: We randomized 318 infants at birth to receive PCV7 in the neonatal or infant schedule or no PCV7. All infants
received 23-valent pneumococcal polysaccharide vaccine (PPV) at age 9 months. Serotype-specific serum IgG for PCV7 (VT)
serotypes and non-VT serotypes 2, 5 and 7F were measured at birth and 2, 3, 4, 9, 10 and 18 months of age. Primary
outcomes were geometric mean concentrations (GMCs) and proportions with concentration $0.35 mg/ml of VT serotype-
specific pneumococcal IgG at age 2 months and one month post-PPV.
Results: We enrolled 101, 105 and 106 infants, respectively, into neonatal, infant and control groups. Despite high
background levels of maternally derived antibody, both PCV7 groups had higher GMCs than controls at age 2 months for
serotypes 4 (p,0.001) and 9V (p,0.05) and at age 3 months for all VTs except 6B. GMCs for serotypes 4, 9V, 18C and 19F
were significantly higher (p,0.001) at age 2 months in the neonatal (one month post-dose2 PCV7) than in the infant group
(one month post-dose1 PCV7). PPV induced significantly higher VT antibody responses in PCV7-primed than unprimed
infants, with neonatal and infant groups equivalent. High VT and non-VT antibody concentrations generally persisted to age
18 months.
Conclusions: PCV7 is well-tolerated and immunogenic in PNG neonates and young infants and induces immunologic
memory to PPV booster at age 9 months with antibody levels maintained to age 18 months.
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Introduction
Every year an estimated 826,000 children under 5 years of age
die of invasive pneumococcal disease (IPD, predominantly
pneumonia, meningitis or sepsis), the majority in 3rd world
countries [1]. Immunization with 7-valent or 9-valent pneumo-
coccal conjugate vaccine (PCV) starting at 6–8 weeks of age
reduces IPD-related morbidity and mortality in vaccinated
children and also reduces IPD incidence in unimmunized people
through herd immunity [2,3,4,5,6,7,8]. More recently, PCVs with
broader serotype coverage (10-valent and 13-valent PCV) have
replaced the 7-valent PCV (PCV7). With funding through the
Global Alliance for Vaccines and Immunisation (GAVI), PCV has
been introduced in 18 developing countries starting at 6 weeks of
age and funding has been approved for a further 28 countries [9].
Inclusion of PCVs in routine immunization programs should
reduce IPD rates in high-risk populations; however, a significant
proportion of disease occurs before children receive PCV due to
the early onset of disease and delays in children receiving
scheduled vaccines [10,11,12]. A multicentre study conducted in
children aged ,3 months living in 3rd world countries, including
Papua New Guinea (PNG), found that the pneumococcus was the
most important cause of serious infections in the second and third
month of life [13]. In PNG, where the present study was
conducted, 26% and 63% of pneumococcal pneumonia in
children occurs before ages 2 and 6 months, respectively, and
approximately one-third of pneumococcal meningitis occurs
before the age of 3 months [14].
Early onset of pneumococcal carriage in the upper respiratory
tract (URT) may result in enhanced susceptibility to disease and
suboptimal responses to subsequent pneumococcal vaccination
[15,16,17]. Pneumococcal carriage occurs in very young infants in
3rd world countries: the median age of first pneumococcal
acquisition in PNG is 19 days and 24 days in The Gambia
[18,19,20].
In view of the high rates of disease and carriage in young
infants, early interventions such as maternal immunization or
accelerated infant immunization schedules, including neonatal
vaccination, should be considered in high-risk populations.
Neonatal immunization may also improve vaccination coverage
in the 3rd world as mothers are more likely to be in contact with
health services around the time of delivery. Coverage for Bacillus
Calmette-Guérin vaccine (BCG) (recommended at birth) is higher
than for vaccines for which a first dose is to be given at age 1
month [10,11,21].
In a randomized trial of PCV7 given to Kenyan infants at 6, 10
and 14 weeks or at 0, 10 and 14 weeks with a booster of PCV7 or a
fractional dose of 23-valent pneumococcal polysaccharide vaccine
(PPV) at 36 weeks of age, neonatal immunization was found to be
safe and immunogenic and primed for memory with no evidence
of induction of tolerance [22].
In PNG we previously demonstrated efficacy of 23-valent
pneumococcal polysaccharide vaccine (PPV) in preventing death
and moderate-severe pneumonia when given at 6 months to 5
years of age; serotype-dependent maturation of antibody responses
supported efficacy data [23,24,25]. A broader range of serotypes
causes IPD in high-risk than in low-risk populations [26,27,28,29],
which may limit effectiveness of PCV programs. In PNG
approximately two-thirds of pneumococcal pneumonia and half
of pneumococcal meningitis in children would be covered by a 13-
valent PCV [30]. A PPV booster would expand serotype coverage.
To address the high burden of pneumococcal disease in young
infants living in resource-poor settings, we have conducted an
open randomized controlled trial to determine the safety and
immunogenicity of PCV7 given either at birth, 1 and 2 months of
age (neonatal group) or according to the standard PNG
immunization schedule at 1, 2 and 3 months of age with a PPV
booster given to all children at age 9 months.
The primary aims of the study were to determine whether:
1. PCV is safe and immunogenic when administered according to
the standard immunization schedule in PNG;
2. neonatal immunization with PCV provides earlier antibody
responses in infancy than immunization starting at 1 month of
age, without compromising safety, especially immunological
safety; and
3. neonatal or early infant immunization with PCV induces
immunological memory to the relevant pneumococcal poly-
saccharides.
Here we present the pneumococcal antibody responses and
clinical safety data.
Methods
A detailed description of the study site and population, process
of assent and consent, enrolment, immunization and follow-up are
reported elsewhere [31]. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1. Here we summarize general
methods used during the study and present in detail methods
pertinent to the results presented here.
Study Area and Participants
We conducted an open randomized controlled trial in the Asaro
Valley in the Eastern Highlands Province of PNG. The valley lies
6u south of the equator and people live at 1500–1900 metres above
sea level. The infant mortality rate is 60/1000 live births and 78%
of infant deaths occur before the age of 6 months [32]. The PNG
Institute of Medical Research (PNGIMR) is located in Goroka
town adjacent to the Goroka General Hospital (GGH), which is
the only tertiary hospital in the province. Between May 2005 and
September 2007 pregnant women were recruited at GGH
antenatal clinic and by local reporters in villages located within
an hour’s drive of Goroka town. Inclusion criteria for enrolment of
newborns were: the intention to remain in the study area for at
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least 2 years, a birth weight .2000 grams, no acute neonatal
infection, no severe congenital abnormality and born in GGH or
brought to GGH within 24 hours of birth. Children of mothers
known to be HIV-positive were excluded.
Ethical Considerations
Ethical approval was obtained from the PNG Medical Research
Advisory Committee and the Princess Margaret Hospital Ethics
Committee in Perth, Australia. This trial is registered at
ClinicalTrials.gov under registration number NCT00219401
(http://clinicaltrials.gov/ct2/show/NCT00219401).
Women who had assented were identified by a study nurse
around the time of delivery at GGH or if they came to GGH
within 24 hours of delivering elsewhere. If still meeting inclusion
criteria after clinical examination by a paediatrician, and if the
mother provided written consent, the child was enrolled into the
study.
An independent data safety monitoring board (DSMB) reviewed
all deaths in a timely manner. Other serious adverse events (SAEs,
i.e. illness requiring hospitalization) were reported to the
independent safety monitor within 48 hours and included in a
quarterly progress report for the DSMB.
Study Procedures and Vaccines
Within 3 days of birth, babies were randomized to receive three
doses of PCV7 (PrevnarTM, Pfizer) intramuscularly either at birth,
1 and 2 months of age (neonatal group) or at ages 1, 2 and 3
months (infant group), or to receive no PCV7 (control group).
Each 0.5 mL dose of PCV7 (batch numbers 15422 and 21933)
contains 20 mg of CRM197 carrier protein coupled to 2 mg of each
saccharide for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F and
0.125 mg aluminium adjuvant. At 9 months of age all children
received PPV (batch number G3836) containing 25 mg of purified
capsular polysaccharides of each of serotypes 1, 2, 3, 4, 5, 6B, 7F,
8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F,
23F and 33 (Pneumovax 23TM, Merck & Co). In addition to the
study vaccines, all children received immunizations according to
the recommended schedule in PNG at that time [33]: BCG at
birth; oral polio vaccine (OPV) at birth, 1, 2 and 3 months;
Hepatitis B vaccine (HepB) at birth, 1 and 3 months; a combined
diphtheria, tetanus, whole cell pertussis, Haemophilus influenzae type
b (Hib) vaccine (DTwP/Hib) at ages 1, 2 and 3 months and
measles vaccination at 6 and 9 months.
Randomization
Eligible infants were randomized using a computer-generated
list of random numbers [31]. As PCV7 had not been evaluated in
this population previously or in a 1-2-3-month schedule, the first
52 infants were randomized to infant and control groups only.
Following review of these infants’ safety data, the DSMB approved
inclusion of the neonatal arm of the study. At enrolment each child
was assigned to neonatal, infant or control group as specified
inside a sealed envelope with the next sequential number.
Laboratory staff were blinded to the group allocation throughout
the study.
Specimen Collection
Umbilical cord and venous or capillary blood samples at 2, 3, 4,
9, 10 and 18 months of age were collected to separate serum for
antibody assays (0.5–2.5 ml). Blood samples were brought to the
laboratory within 2 hours of collection. Serum samples were
aliquotted and stored at 220uC until they were analysed.
Pneumococcal Capsular Polysaccharide (CPS) ELISA
Serum serotype-specific IgG to PCV7 serotypes (VT) and to
non-PCV7 serotypes (NVT) 2, 5 and 7F which commonly cause
IPD in Papua New Guinean children [14,26] were measured using
a WHO standardized pneumococcal enzyme-linked immunosor-
bent assay (ELISA) [34]. Briefly, microtitre plates (Greiner,
Germany) were coated with the specific pneumococcal capsular
polysaccharide (CPS) antigens for 5 hours at 37uC. In order to
enhance the specificity of the assay by removal of non-specific
antibodies, the reference serum 89SF (FDA, Bethesda, MD) was
pre-absorbed overnight with 10 mg/ml cell wall polysaccharide
(CWPS) and serum samples with 10 mg/ml CWPS and 5 mg/ml
purified serotype 22F polysaccharide. Alkaline phosphatase goat
anti-human IgG conjugate and pnitrophenyl phosphate (Sigma,
USA) were used for antibody detection. Each plate contained high
and low in-house control sera to assess intra- and inter-assay
variations.
Reactogenicity and Morbidity Surveillance
Children were observed for 1 hour and reactogenicity again
assessed 48–96 hours post-vaccination [31]. Morbidity data were
collected by passive surveillance at the PNGIMR clinic, routine
check of parent-held health books, review of admissions to the
GGH paediatric ward, and weekly visits to study participants’
houses by village reporters throughout the first year and fortnightly
from age 12–18 months. All children with moderate or severe
pneumonia, suspected meningitis or sepsis were referred to a
paediatrician. Blood culture and a pernasal swab were to be
collected if a child had temperature .38uC or signs of moderate
or severe pneumonia (cough, raised respiratory rate and lower
chest wall indrawing with or without enlarged liver or cyanosis) or
suspected meningitis. Blood culture and characterisation of
pneumococcal and Haemophilus influenzae isolates were performed
according to standard methods established at PNGIMR
[14,26,35].
Outcomes of the Study
The primary outcomes for the study were:
1. immunogenicity of PCV7 under an accelerated 1-2-3-month
schedule (aim 1) which was assessed by comparing serotype-
specific IgG concentrations and the proportions of children
with VT serotype-specific antibody concentrations $0.35 mg/
ml (the serologic correlate of protection against IPD following
PCV [36,37]) at 2, 3 and 4 months of age in infants vaccinated
according to the infant schedule with those in infants who had
not received PCV7;
2. comparison of serotype-specific IgG concentrations and the
proportions of children with serotype-specific antibody con-
centrations $0.35 mg/ml [36,37]between the neonatal and
infant groups at age 2 months for PCV7 serotypes (aim 2);
3. comparison of serotype-specific IgG concentrations and the
proportions of children with VT serotype-specific antibody
concentrations $0.35 mg/ml one month post-PPV between
PCV-vaccinated children and controls (who had received PPV)
(aim3); and
4. safety of 3 doses of PCV7 in PNG infants when administered
according to the standard immunization schedule in PNG (1, 2
and 3 months) and when started at birth (0, 1, and 2 months);
rates of local and systemic reactions and hospitalization rates
were compared between groups.
Neonatal Pneumococcal Conjugate Vaccination in PNG
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Secondary outcomes were VT serotype-specific IgG concentra-
tions and proportions of samples with concentration $0.35 mg/ml
at ages 3, 4, 9 and 18 months and also serotype-specific IgG
concentrations and proportions of responders ($0.35 mg/ml) for
non-PCV7 PPV serotypes 2, 5 and 7F at ages 2, 3, 4, 9, 10 and 18
months.
Statistical Analyses
Details of sample size calculations have been reported
previously [31]. Power analyses conducted during study design
showed that a sample size of 100 per vaccination group allows a
70% seroprotection rate ($0.35 mg/ml) to be estimated with a
95% confidence interval of 60% to 79%. This sample size gives
80% power to detect a reduction to 50% from this seroprotection
rate as being inferior and an increase to 87% as being superior at a
significance level of p,0.05. For the non-inferiority analyses, using
a margin of 10%, the sample size has equivalent power to detect a
rate of 78% as being non-inferior to 70%.
Per protocol analyses included all children meeting inclusion
criteria who received PCV7, PPV and DTP/Hib according to
protocol and had appropriate samples collected. Intention-to-treat
analysis included all children who met the inclusion criteria for the
study. Both intention-to-treat analyses and per protocol analyses
were performed and gave similar results. Therefore results of per
protocol analyses are presented here.
Data were analysed using SPSS (version 15.0, Chicago, IL,
USA). Serotype-specific antibody concentrations were log-trans-
formed and geometric mean concentrations (GMCs) and 95%
confidence intervals (CIs) calculated. Exact confidence intervals for
binomial proportions were calculated using the Clopper-Pearson
method. Categorical variables were compared using the Pearson
chi-squared test. The Mann-Whitney or Kruskal-Wallis tests were
used to compare continuous data in two or three groups,
respectively. We used Pearson chi-squared or Fisher’s exact tests
to calculate p-values for group differences in frequency of adverse
reactions to vaccination, except where a vaccine was administered
on more than one occasion to each child in which cases we used a
logistic regression model incorporating general estimating equa-
tions to calculate this p-value. Differences were considered
significant if the p-value was less than or equal to 0.05.
In addition, a post-hoc superiority analysis was performed by
calculating the exact, unconditional, 2-sided 95% CIs on the
difference in proportions of children with antibody concentration
$0.35 mg/ml (considered superior in the neonatal group if the
95% CI does not include 0). If superiority was not achieved, non-
inferiority of the neonatal schedule was assessed by determining
whether the 2-sided 95% CI for the difference in proportions of
children with antibody concentration $0.35 mg/ml between the
two groups (neonatal–infant) does not exceed 20.10.
Poisson regression was used to adjust age-specific incidence and
hospitalization rates (/1000 person-days) for gender. Incidence
rate ratios (IRRs) and 95% CIs relative to the control group were
used to assess clinical safety of infant and neonatal schedules.
Person-time-at-risk was used to determine age-specific hospital-
ization rates and took into account age at entry (though all were
aged ,3 days) and exit from the study.
Results
Population Characteristics and Follow-up
Between May 3, 2005 and September 13, 2007, 318 newborns
were randomized to the neonatal (104), infant (105) or control
group (109) of which 101, 105 and 106 were subsequently enrolled
in the respective groups. Figure 1 illustrates the number of children
remaining in the study at different ages during the study period.
Overall, 77% completed 18 months of follow-up (77%, 83% and
71% in the neonatal, infant and control groups, respectively, chi-
squared= 4.36, 2 df, p = 0.11). Details of loss to follow-up and
protocol violations have been reported previously [31]. Six
children were excluded from analysis after a delayed diagnosis of
contraindicated medical conditions, including HIV and congenital
heart disease. There were two deaths during the study period, one
from severe burns and gastroenteritis while the other died from
pneumonia prior to receiving the scheduled PCV7; the post-PCV7
deaths were not related to the study vaccine [31]. Parental
withdrawal and migration out of the study area were the main
reasons for losses to follow-up in the first and later months of the
trial, respectively. There were 14 protocol violations relating to
allocated immunization schedule: 6 related to 7vPCV, 4 related to
PPV and 4 children received DTP (at a government clinic) rather
than DTP/Hib (Figure 1) [31].
The obstetric and newborn characteristics were similar in the
neonatal, infant and control groups except for fewer boys in the
neonatal group (43%) than in either infant (57%, p= 0.045) or
control groups (61%, p= 0.008) (Table 1). No differences in
population characteristics were found between children lost to
follow-up and those followed to age 18 months (data not shown).
Children received vaccines in a timely fashion at comparable ages
[31].
Reactogenicity and Safety
No serious reactions were observed within an hour of
vaccination. The vaccines were generally well tolerated (Table
S1). Overall, children immunized according to the infant PCV7
schedule experienced more local side effects in response to PCV7
(22/287) than children vaccinated according to the neonatal
PCV7 schedule (7/280, p= 0.020) and similar trends were
observed for DTwP/Hib (infant group 48/284; neonatal group
26/261, p = 0.058) and Hepatitis B (infant group 8/288; neonatal
groups 1/260, p = 0.059) (Table S1).
A total of 1243 illness episodes (355 in neonatal, 444 in infant
and 444 in control groups) were documented from time of
enrolment to completion of follow-up. Table S2 shows age-specific
gender-adjusted incidence rates for moderate/severe pneumonia,
all acute lower respiratory infections (ALRIs) and hospitalization
rates in neonatal, infant and control groups. Adjusted incidence
rates of acute lower respiratory infections (ALRIs) up to age 18
months were 1031 (n= 128), 1141 (n= 166) and 1275 (n= 162) per
1000 person-years at risk in the neonatal, infant and control
groups, respectively, of which 40% were classified as moderate or
severe pneumonia. There were no significant differences in ALRI
incidence rates or hospitalization rates between neonatal, infant
and control groups (Figure 2, Table S2). The number of SAEs was
similar irrespective of vaccination schedule: 48 SAEs in the
neonatal PCV7 group, 45 in the infant PCV7 group and 47 in
children who had no PCV7 (379, 324 and 362/1000 person-years
at risk, respectively). No SAEs were related to vaccination.
A total of 185 blood cultures were collected, 147 of which were
from children aged ,12 months. Streptococcus pneumoniae was
isolated from 7 samples (3.8%, 95% CI 1.5–7.6%). All 7 isolates
were from children aged ,12 months, giving an estimated IPD
incidence rate of 4762/100,000/annum (95% CI 1936–9665) in
the first year of life. Three were isolated from children in the
neonatal group (serotypes 5 and 8; the other was 12F isolated
together with H. influenzae type C from an HIV–positive child
subsequently excluded from the study). Serotype 19A was isolated
from a child in the infant group and serotypes 2, 18C and
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serogroup 33 were isolated from unvaccinated children. No other
significant pathogens were grown.
Overview of Pneumococcal Serotype-Specific Antibody
Responses Throughout the Study
Geometric mean antibody concentrations (and 95% CIs) for
PCV7 serotypes and three NVTs from birth to age 18 months
according to study group are shown in Figure 3. Table 2 shows the
number of samples tested and the proportions of children with
serotype-specific IgG concentration $0.35 mg/ml at each time
point (with 95% CIs; shown graphically in Figure S1). GMCs and
the proportions of samples with the more conservative cut-off of
$1 mg/ml are in Table S3.
Fewer samples were available for pneumococcal antibody assays
at birth than at subsequent time points as study personnel were not
always available at the time of delivery (Table 2). Generally, serum
volumes were adequate to measure antibodies to all serotypes.
Fewer assays were conducted for serotype 5 in view of some
concerns regarding the reliability of the assay.
The high levels of maternal antibody in all groups at birth
declined over the first 2 months of life; in the control group the
decline continued to its lowest levels at age 4 months (Figure 3).
VT antibody concentrations were higher in both infant and
neonatal PCV7 groups than in controls from 2 to 9 months of age
for serotype 4 and from 3 to 9 months of age for all other PCV7
serotypes except for serotype 19F for which GMCs were high in all
groups, with no difference between vaccine and control groups at
age 9 months (Figure 3, Table S3). From 2 to 10 months of age
more children (generally .80%) in both PCV groups had
antibody concentrations $0.35 mg/ml for all VTs than in the
control group, except for serotype 19F, where the proportion with
a protective level in the control group were also high (Figure S1).
The more conservative 1 mg/ml cut-off was more discriminatory
in showing differences in antibody responses between vaccinated
and unvaccinated children (Table S3). At age 4 months GMCs of
VT-specific antibody were higher in the infant group (one month
after the third dose of PCV7) than in the neonatal group that had
received the third dose of PCV7 two months earlier (Figure 3,
Table S3); a comparable high proportion of children in both
groups had antibody concentrations $0.35 mg/ml for PCV7
serotypes (averages varying between 72 and 98%), except for
serotype 23F for which fewer children in the neonatal than infant
group had concentrations $0.35 mg/ml (Figure S1). Generally
high antibody concentrations persisted to 18 months of age with
.75% of children having antibody concentrations $0.35 mg/ml
for PCV7 serotypes (and .90% for PCV7 serotypes 6B, 9V, 14
and 19F).
IgG concentrations to non-PCV7 serotypes 2 and 7F were
similar in PCV7-vaccinated and control groups at all ages, the
lowest levels being at age 3–4 months. For non-PCV7 serotype 5,
IgG concentrations and the proportion of samples with concen-
tration $0.35 mg/ml were higher at ages 3–4 months in children
given PCV7 than in controls (Figure 3, Table 2, Table S3, Figure
S1). Responses for NVTs one month after PPV at age 9 months
were good in all children (mean fold increases 2.9–3.3 for serotype
7F, 2.2–3.3 for serotype 5 and 8–11.6 for serotype 2) and antibody
levels were maintained to age 18 months.
There were no significant differences in serotype-specific IgG
concentrations between males and females.
Immunogenicity of PCV Under the Standard PNG 1-2-3-
month Schedule
At age 2 months IgG concentrations for serotypes 4 and 9V
were significantly higher one month after the first dose of PCV7
than in controls (serotype 4 GMC 0.96 mg/ml (95%CI 0.78–1.18)
in infant group vs 0.46 (0.37–0.56) in control group, p,0.001;
serotype 9V 0.82 mg/ml (0.69–0.96) in infant group vs 0.66 mg/ml
(0.53–0.84) in controls, p = 0.044); there were no significant
differences for the other VTs at this age. However, GMCs for
VTs, other than serotype 6B, were significantly higher in the
vaccinated (GMC range 0.56–2.82 mg/ml) than in the unvacci-
nated group (GMC range 0.21–1.03 mg/ml) one month after the
2nd dose (age 3 months) and for all VTs after the 3rd dose (age 4
months) (GMC 1.52–4.68 vs 0.2–0.94 mg/ml) (Figure 3 and Table
S3). There were no statistical differences in the proportions of
children with antibody concentration $0.35 mg/ml at 2 months of
age between the infant group (range 71.0–97.8%) and controls
(57.9–97.9%); however, at 3 months of age this proportion was
significantly higher in the infant group than in unvaccinated
Figure 1. Flow diagram of the study [31]. Flow diagram indicating number of women who assented and children enrolled into the study,
randomized to neonatal or infant PCV7 or control groups and number excluded or lost to follow-up in the course of the study. PCV= 7-valent
pneumococcal conjugate vaccine; N=Neonatal group; I = Infant group; C = control group; LTFU= lost to follow-up (includes not located, withdrew
consent, migration). Numbers (n) are total excluding LTFU and protocol violations.
doi:10.1371/journal.pone.0056698.g001
Table 1. Obstetric and newborn characteristics according to
randomization to neonatal or infant PCV7 schedule or to
control group.
Neonatal Infant Control
Age mother, years 25.7 (5.6) 25.3 (5.6) 25.4 (5.6)
Gravida:
1 27% 36% 35%
2 30% 19% 24%
3 22% 21% 17%
4 or more 21% 24% 24%
Smoking in pregnancy 9% 4% 11%
Tetanus vaccination in pregnancy 94% 94% 97%
Maternal haemoglobin 12.2 (1.7) 12.1 (1.6) 12.1 (1.4)
Foetal distress 4% 1% 5%
Male newborn 43% 57% 61%
Delivery by caesarean 2% 2% 1%
Gestational age, weeks 39.4 (1.2) 39.5 (1.3) 39.6 (1.0)
Birth weight, g 3245 (440) 3310 (435) 3315 (520)
Birth length, cm 49.9 (3.0) 49.9 (3.9) 50.7 (3.3)
Head circumference, cm 33.2 (1.6) 33.5 (1.8) 33.5 (1.6)
Continuous variables are expressed as mean with standard deviation. Missing
data resulted in varying denominators for the following variables: age mother,
neonatal, n = 100; infant, n = 103; control, n = 108; smoking pregnancy,
neonatal, n = 95; infant, n = 93; control, n = 102; tetanus vaccination, neonatal,
n = 89; infant, n = 87; control, n = 94; foetal distress, neonatal, n = 89; infant,
n = 85; control, n = 94; delivery, neonatal, n = 100; infant, n = 98; control, n = 107;
gestational age, neonatal, n = 103; infant, n = 101; control, n = 102; birth weight,
neonatal, n = 103; infant, n = 101; control, n = 102; birth length, neonatal, n = 98;
infant, n = 97; control, n = 98; head circumference, neonatal, n = 102; infant,
n = 94; control, n = 97; maternal haemoglobin, neonatal, n = 91; infant, n = 87;
control, n = 83.
doi:10.1371/journal.pone.0056698.t001
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children for 5 of the 7 VT serotypes (serotype 4 (94.4% vs 31.8%),
9V (91.0% vs 45.9%), 14 (94.4% vs 74.1%), 18C (79.8% vs 41.2%)
and 19F (100% vs 88.2%)) and at 4 months of age for all 7 VT
serotypes (range 90.0–100% vs 30.2–90.8%) (Table 2 and Figure
S1).
Immunogenicity of Neonatal Immunization with PCV
Despite the high background levels of maternally derived
antibody (generally .80% had levels $0.35 mg/ml), GMCs were
significantly higher at 2 months of age in the neonatal than in the
infant group for 4 of the 7 VTs (serotypes 4 (GMC 1.54 mg/ml
(95%CI 1.24–1.91) vs 0.96 (0.78–1.18), p = 0.002), 9V (1.21 (1.02–
1.45) vs 0.82 (0.69–0.96), p = 0.008), 18C (0.76 (0.62–0.93) vs 0.49
(0.42–0.57), p = 0.001) and 19F (2.84 (2.42–3.34) vs 1.98 (1.69–
2.32), p = 0.003), Figure 3 and Table S3). The proportions with
antibody level $0.35 mg/ml were higher in the neonatal than in
the infant group for all VTs at 2 months of age (range 80.9–100%
vs 71–97.8%), but differences between the groups were not
significant as the majority of children had antibody levels above
this cut-off (Table 2). Post-hoc analysis of the differences in
proportions of children with protective antibody levels at age 2
months did not demonstrate superiority of 2 doses in the neonatal
group over 1 dose in the infant group (Figure S2). However, all
antibody responses to VTs in the neonatal group were non-inferior
to those in the infant group at age 2 months (Figure S2).
Induction of Immunologic Memory Following Neonatal
and Early Infant PCV7 Schedules
PPV given at 9 months of age induced antibody responses in
both PCV7-primed and unprimed infants, as demonstrated by the
rise in serotype-specific antibody concentrations between 9 and 10
months of age (Figure 3 and Table S3). However, average fold
change in serotype-specific IgG concentrations between pre- and
post-PPV vaccination (Figure 4) was greater in PCV7-primed than
in unprimed children (except for serotypes 4 and 14 in the infant
group for which the fold change was not significantly different
from that in the control group). The mean increase in the VT IgG
concentration was 6.4-fold in the PCV-vaccinated groups com-
pared with 1.9-fold in the control group. There were no significant
differences in the PPV-induced rise in IgG concentrations between
the neonatal and infant vaccination groups. At age 10 months
antibody levels were significantly higher in children primed with
PCV7 than in the control group (GMC range 2.98–11.83 mg/ml
vs 0.57–3.11) with no difference between the neonatal and infant
groups except for serotype 23F, for which levels were higher in the
infant (GMC 5.55 mg/ml (95%CI 4.15–7.41)) than in the neonatal
group (GMC 3.00 mg/ml (2.13–4.24), p = 0.009) (Table S3). At
age 10 months, one month post-PPV, 91–100% of PCV-primed
children had antibody levels $0.35 mg/ml compared with 67–
100% in children who had received only PPV, the lowest
proportion being for serotype 23F (91% in neonatal, 94% in
infant and 67% in control groups). All children had antibody levels
$0.35 mg/ml to serotype 19F (Table 2).
Discussion
This is one of only two studies of neonatal PCV and the only
study to include an unimmunized control group and a booster
with a standard dose of PPV. Follow-up to age 18 months and
detailed investigation of T-cell responses have provided important
safety data, especially immunological safety.
We found that PCV7 is well tolerated and immunogenic in the
PNG standard 1-2-3-month schedule, relevant to PNG policy-
makers who plan to introduce a universal PCV program in 2013.
The neonatal PCV7 schedule was not only safe and immunogenic,
but GMCs for 4 of the PCV7 serotypes were higher at age 2
months in the neonatal than in the standard schedule group,
despite high levels of maternally derived antibody limiting the
ability to measure infant-derived antibody responses. With high
maternal antibody titres declining at different rates, the impact of a
neonatal priming PCV dose is hard to measure as the response to
Figure 2. Risk for hospitalization. Gender-adjusted incidence rates of hospitalization (695% confidence intervals) during the 1st month, 1–,4
months (PCV immunization ongoing), 4–,10 months (PCV immunization completed), and 10–18 months (post-PPV) of life for the neonatal PCV
(green bars), infant PCV (red bars) and control group (blue bars).
doi:10.1371/journal.pone.0056698.g002
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the second dose of PCV is measured at 2 months of age when a
significant proportion of maternal antibody is still present. We
cannot exclude that neonatal PCV responses are limited by
interference of maternal antibodies or a reduced capacity of
neonatal B cells to respond to some serotypes in PCV7. We did not
find impairment in the overall response to the 3 dose PCV series
when started at birth. Assessment of polysaccharide-specific
memory B-cells or functional opsonophagocytic antibody may
inform this issue. Importantly, we have previously reported that
neonatal PCV7 primes T-cell responses with no bystander effects
on other T-cell responses and no evidence of T-cell tolerance
[38,39]. There was also no clinical evidence of deleterious effects
Figure 3. Age-specific geometric mean serotype-specific antibody concentrations pre-and post-PCV7 at 0-1-2 or 1-2-3-months or
no PCV7. Geometric mean (GM) concentrations and 95% confidence intervals of serotype-specific IgG antibodies for PCV7 serotypes and non-PCV7
serotypes 2, 5 and 7F in the neonatal (N) (PCV7 at birth, 1 and 2 months), infant (%) (PCV7 at 1, 2, and 3 months) and control group (n) (no PCV7). All
children received PPV at 9 months of age.
doi:10.1371/journal.pone.0056698.g003
Figure 4. Geometric mean fold rise in antibody for PCV7-serotypes following PPV at age 9 months. To demonstrate immunological
memory, PPV was administered at 9 months of age and the mean (and 95% CI) fold changes in PCV7-serotype-specific GMCs were calculated and
compared for the neonatal (N), infant (%) and control group (m), with significant differences between groups (p,0.05) indicated with *.
doi:10.1371/journal.pone.0056698.g004
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of neonatal immunization: in fact neonatal immunization
appeared to reduce the risk of local reactions to PCV7 and
possibly to other infant vaccines. The reduction in local
reactogenicity after neonatal immunization is an interesting and
potentially important finding but to establish the reason for this
would require further specific investigation. It should be noted
that, after an initial 1-hour post-vaccination examination, for
logistical reasons we assessed reactogenicity 48–96 hours post-
vaccination. If we had been able to assess children earlier than 48
hours post-vaccination, we might have detected more reactions to
vaccination, though, importantly, no serious side effects following
neonatal or early infant PCV7 schedules were identified. While we
have presented ALRI incidence data, the study was not powered
to formally investigate the impact of accelerated PCV schedules on
ALRI morbidity.
The high levels of maternal antibody in early infancy and the
differences at specific time points between the neonatal and infant
groups with regard to the number of doses and the time elapsed
since last dose have to be considered when comparing antibody
responses between neonatal and infant schedules: for example, at
age 2 months the neonatal group will have received 2 doses
compared with only 1 in the infant group, while at age 4 months, 2
months will have elapsed since the 3rd dose of PCV7 in the
neonatal group but only 1 month since the last dose in the infant
PCV7 group. The latter may explain lower serotype-specific
antibody levels in the neonatal than in the infant group at age 4
months. This difference was no longer evident at age 9 months.
Both infant and neonatal PCV7 schedules induced immuno-
logical memory to a PPV booster at age 9 months with higher VT
antibody levels one month post-PPV than in unprimed children
that were generally maintained to age 18 months. Children also
elicited good IgG responses to non-PCV7 serotypes 2, 5 and 7
following PPV immunization. However, we discontinued mea-
surement of IgG to non-PCV7 serotype 5 in view of the higher
titres for this serotype seen in PCV7-immunized children than in
controls. Kieninger et al also found antibody responses to serotype
5 following PCV7 but no functional activity, suggesting cross-
reactivity with another bacterial polysaccharide which requires
further investigation [40]. Functional antibody assays could not be
done on samples from our PNG study until now due to financial
constraints but measurement of opsonophagocytic antibody assays
to all PCV7 serotypes will commence shortly.
We included a standard PPV dose at age 9 months not only to
investigate immunological memory but also because of the
demonstrated efficacy of PPV in prevention of death and serious
ALRI in an earlier study among Papua New Guinean children
[23,25]. A PPV booster following PCV priming could provide the
broader serotype coverage required in high-risk populations and
assist in preventing replacement disease reported following
introduction of PCVs [41,42,43]. The good antibody responses
to PPV at age 9 months in PCV7-primed and unprimed Papua
New Guinean children were consistent with our earlier study in
PNG [24] and with those in Fiji, Kenya and The Gambia
[22,44,45,46]. However, there have been concerns of hypore-
sponsiveness following PPV vaccination [47,48]. While the clinical
significance of hyporesponsiveness remains unclear, this phenom-
enon requires further investigation, specifically in populations with
high pneumococcal carriage rates. Preliminary data following a
challenge dose of PPV at age 3–5 years in children who took part
in the present PNG study compared to unimmunized controls
showed no deleterious effect on antibody persistence or responses
to a challenge dose and no difference in pneumococcal carriage
rates between groups (ClinicalTrials.gov NCT01414504) [49,50].
However, there was no group of children who received PCV with
no PPV and there was a prolonged time interval between PPV and
challenge. Therefore another study is underway in PNG in which
we are investigating immunological memory at age 23 months
following PPV at age 9 months in children primed either with 10-
valent or 13-valent PCV (ClinicalTrials.gov NCT01619462).
Our findings are consistent with those from the only other study
of neonatal PCV7, conducted in Kenya [22], in which antibody
responses were similar following PCV7 at 0-6-14 weeks or 6-10-14
weeks. Antibody levels in the Kenyan study were remarkably
similar at age 5 months to our findings at age 4 months (one
month after 3 doses in Kenya compared with 2 months after 3
doses of PCV7 in PNG). However, more children had serotype-
specific antibody titres $1 mg/ml at 18 weeks following the 0-10-
14-week PCV7 schedule in Kenya than at 16 weeks in PNG
following a 0-4-8-week schedule, suggesting that a longer interval
between neonatal and second dose may be preferable.
Interestingly, a high proportion of children in our study,
including those in the control group, had antibody concentrations
$0.35 mg/ml to serotype 19F throughout the study period. This
serotype was the most commonly carried in the population.
The United Nations’ 4th Millennium Development Goal (MDG)
aims to reduce childhood mortality by two-thirds by 2015 and
WHO has recommended investigation of neonatal immunization
to reduce the high mortality in early infancy [51]. This MDG will
not be achieved without addressing the enormous burden of
pneumonia and neonatal mortality [52]. With pneumonia
responsible for more than 2 million childhood deaths, the majority
in the first 6 months of life, early immunization is vital. The
inclusion of a neonatal dose of PCV would achieve this and also
improve PCV coverage [53,54] without compromising effective-
ness. The additional use of a PPV booster may also offer
protection against important non-PCV serotypes such as serotype
2 [14,28] as well as boosting for the PCV serotypes. These results
justify further studies of neonatal immunization, including
comprehensive clinical trials with second generation PCVs
covering additional important serotypes causing invasive pneu-
mococcal disease.
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Figure S1 Proportions of children with serotype-specific
antibody titre $0.35 mg/ml by age in PCV7-immunized
and unimmunized children. The proportions of children (and
95% confidence intervals) with IgG antibody concentration above
the serologic correlate of protection ($0.35 mg/ml), specific for
PCV7 serotypes and non-PCV7 serotypes (2, 5 and 7F), in the
neonatal (N) (PCV7 at birth, 1 and 2 months), infant (%) (PCV7 at 1,
2, and 3 months) and control group (m) (no PCV7). All children
received PPV at 9 months of age.
(TIF)
Figure S2 Superiority or non-inferiority of the neonatal
versus infant PCV7 schedule at 2 months of age. We
calculated the exact, unconditional, 2-sided 95% CIs on the
difference in proportions of children with serotype-specific IgG
concentration $0.35 mg/ml after 2 doses of PCV7 in the neonatal
group (at birth and 1 month) compared with that found after 1
dose of PCV7 in the infant group (at 1 month of age). The results
indicate that the responses in the neonatal group were non-inferior
to those in the infant group.
(TIF)
Table S1 Frequency of local and systemic side effects to
PCV7, PPV and routine EPI vaccines.
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confidence limits for rates (95% CL, LCL and UCL) of
(A) moderate/severe pneumonia, (B) any acute lower
respiratory infection (ALRI) and (C) any hospitalization
among children who received 7-valent pneumococcal
conjugate vaccine in a 0-1-2-month (neonatal group) or a
1-2-3-month (infant group) schedule and among con-
trols.
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percentage with serotype-specific antibody titre $1 mg/
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and controls.
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